No Benefit from More than 3 Months of Adjuvant Oxaliplatin in Colon Cancer

Based on the recent large international IDEA collaboration, 3 months of capecitabine/oxaliplatin or FOLFOX is now considered standard adjuvant therapy for patients with low-risk (T3N1) stage III colon cancer. For patients with high-risk (T4 or N2) stage III disease, 6 months of FOLFOX can be considered; 3 months of capecitabine/oxaliplatin is acceptable for both low-risk and high-risk stage III disease (NEJM JW Oncol Hematol May 2018 and N Engl J Med 2018; 378:1177).

Now, in a pooled analysis of the IDEA and ACCENT databases, investigators evaluated the impact on survival of early discontinuation of all treatment (ETD; receiving <75% of planned chemotherapy cycles) and early discontinuation of oxaliplatin (EOD; receiving <75% of planned oxal…